NEOGENOMICS (NEO)·Q4 2025 Earnings Summary
NeoGenomics Beats Q4 on NGS Strength, Guides to 10% Growth with MRD Launch
February 17, 2026 · by Fintool AI Agent
NeoGenomics (NEO) delivered its 10th consecutive quarter of positive adjusted EBITDA, beating both revenue and earnings estimates on accelerating NGS test adoption in the community oncology channel. Q4 revenue grew 11% YoY to $190M, while NGS revenue surged 23% . The company issued FY 2026 guidance calling for ~10% revenue growth and 27-31% adjusted EBITDA growth, with modest contribution expected from the imminent RaDaR ST MRD launch . Management outlined a deliberate shift from volume-driven to AUP-driven growth, with plans to add 25+ sales specialists for the MRD launch .
Did NeoGenomics Beat Earnings?
NeoGenomics beat across the board in Q4 2025:
Values retrieved from S&P Global
The beat was driven by:
- NGS revenue grew 23% YoY in Q4 and 22% for the full year, "well ahead of the market growth rate"
- Revenue per test increased 5% to $488, or 7% excluding recently acquired Pathline tests, reflecting mix shift toward higher-value assays
- Clinical volume grew 11% to 356K tests, with same-store volume up 6%
CEO Tony Zook emphasized the strength in community oncology: "Our ability to successfully pull innovation through the community channel, where we enjoy a leadership position and where approximately 80% of all cancer care is delivered today" .
Ask Fintool AI AgentWhat Did Management Guide for 2026?
NeoGenomics initiated FY 2026 guidance with meaningful EBITDA expansion:
Key assumptions in the guidance:
- RaDaR ST MRD revenue in the "mid-single-digit millions" — modest contribution in launch year
- PanTracer LBx (liquid biopsy) with "modest revenue contribution"
- Non-clinical revenue down low-to-mid single digits YoY due to macro trends in pharma/biotech
- ~100 basis points of margin expansion YoY
How Did the Stock React?
NEO shares rose +1.9% in regular trading to $11.38, though aftermarket trading showed a pullback to $11.09 (-2.5% from close).* The muted reaction likely reflects:
- Guidance largely in-line with expectations (~10% growth)
- MRD contribution remaining modest in 2026
- Continued GAAP losses despite adjusted profitability
Values retrieved from S&P Global
The stock is up 141% from its 52-week low of $4.72, trading at $11.38 vs. a 52-week high of $13.74.*
What Changed From Last Quarter?
Several notable developments since Q3 2025:
RaDaR ST Patent Litigation Resolved
Management highlighted the "successful resolution of RaDaR ST patent litigation" , removing a key overhang ahead of the MRD launch. IP litigation costs totaled $11.3M for FY 2025, including settlement payments .
Margin Trajectory Inflected
While adjusted gross margin compressed ~160bps YoY to 46.4% in Q4 (vs. 48.0% in Q4 2024) , management is guiding to ~100bps of EBITDA margin expansion in 2026 through:
- Digital pathology initiatives
- Automation and AI deployment
- Single LIMS implementation
- Lab footprint optimization
Sales Force Expansion Driving Share Gains
Sales headcount increased to 165 from 140 in 2024, with ~75% of community oncologists new to NEO in 2025 ordering 5+ tests . Five products launched in 2023 now represent 25% of 2025 clinical revenue .
Ask Fintool AI AgentKey Product Catalysts
RaDaR ST MRD Launch (February 2026)
NeoGenomics is launching RaDaR ST for minimal residual disease monitoring in solid tumors, initially for:
- HPV-negative head and neck cancer: ~20K new diagnoses, ~60K prevalent
- HR+/HER2- breast cancer: ~210K new diagnoses, ~1.1M prevalent
The company targets the $20B+ MRD market with detection sensitivity "as low as 1 part per million" . Management is also developing next-gen MRD based on whole genome sequencing, with MolDx submissions planned for 2026-2027 .
PanTracer Pro Launch
The new PanTracer Pro product delivers:
- Single-order workflow for therapy selection
- 8-10 day turnaround for results
- 12+ companion diagnostic IHC tests
Near-Term Catalysts
Management outlined four key catalysts for 2026 :
- RaDaR ST launch for HPV- Head & Neck and subset of Breast
- PanTracer LBx MolDx reimbursement
- Expanded indication reimbursement for RaDaR ST
- Above-market NGS growth
Full Year 2025 Performance
Clinical revenue grew 15% YoY (13% excluding Pathline), with NGS growing 22% for the full year .
Balance Sheet & Capital Allocation
Cash and equivalents totaled $160M at quarter-end, down from $367M at year-end 2024 . The decline reflects:
- $201M convertible debt repayment
- $27M capex (down from $41M in 2024)
- $6.5M for Pathline acquisition
Remaining convertible debt stands at $342M .
Ask Fintool AI AgentQ&A Highlights
Volume Rationalization Strategy
Management outlined a deliberate shift from volume-driven to AUP-driven growth. CEO Tony Zook explained the rationale:
"We had a contract... that was a high volume, low value-added opportunity for us. The AUPs were in the low $200 range... our resources are better used and focused in the areas where we're seeing higher margin opportunities."
The new model inverts historical growth drivers: AUP growth in upper single digits (vs. low single digits historically), with volume in lower-to-mid single digits (vs. upper single digits historically). Critically, NGS now represents over one-third of clinical revenue on just 9-10% of volume .
Quarterly volume cadence: Q1 sequential volumes expected down (similar to Q4), Q2 flat YoY, then resuming growth in Q3/Q4 .
RaDaR ST Launch Details
- Full clinical launch by end of February 2026 for HPV-negative head & neck and HER2-negative breast
- New ENT sales team being hired — ENTs haven't been a traditional call point for NeoGenomics
- Additional indications submitted to MolDX; management expects approval in "latter half of this year" — would represent upside to guidance
- 25+ oncology sales specialists to be added by Q3 2026 for expanded indications
PanTracer LBx Reimbursement Timeline
Management noted MolDX is averaging 4-5 turns for new tests (~12-month cycle). NeoGenomics has responded to all MolDX questions and is "in waiting mode." They view approval as "when, not if" and guided conservatively for H2 2026 revenue only .
LIMS Integration Roadmap
The company is migrating from 8 legacy LIMS systems to 1 unified platform:
- 2026 focus: Accessioning and molecular/NGS workflows
- 2027-2028: Full benefits from retiring legacy systems and technical debt
- Near-term wins: Workflow optimization and analytics visibility for real-time sample tracking
CEO Zook: "This is foundational for us... I maintained that we're still in the early innings relative to gross margin expansion opportunities."
Pharma Services Outlook
The non-clinical pharma business (~5-6% of total revenue) continues to face headwinds:
- 2026 expectation: 5-10% erosion (better than 2025's 24% decline)
- Return to growth: Expected in 2027
- RaDaR ST as catalyst: "Robust opportunity pipeline" developing with legacy and new pharma users
Gross Margin Expansion Drivers
CFO Abhishek Jain guided to 100-120 basis points of gross margin expansion in 2026, flowing through to adjusted EBITDA improvement. Drivers include:
- Direct client bill pricing increases (Q1)
- Managed care pricing increases (full-year impact)
- RCM initiatives to close gap between expected and actual reimbursement
- Mix shift toward higher-margin NGS tests
Ask Fintool AI AgentRisks and Concerns
- Continued GAAP losses: Net loss of $108M in FY 2025 vs. $79M in 2024, driven by $28M impairment charges and $11M IP litigation costs
- Non-clinical headwinds: Pharma/biotech macro weakness pressuring non-clinical revenue, expected to decline 5-10% in 2026
- MRD execution risk: RaDaR ST entering a competitive market with established players; 2026 contribution expected to be modest
- Near-term volume pressure: Q1/Q2 volumes expected flat-to-down as low-value contracts roll off
The Bottom Line
NeoGenomics delivered a clean beat with its 10th consecutive quarter of positive adjusted EBITDA and accelerating NGS growth. The 2026 setup is compelling: RaDaR ST launch opens the $20B+ MRD market, while operational improvements should drive ~100bps of margin expansion. However, execution on MRD and the path to GAAP profitability remain key investor debates. At $11.38, the stock trades at ~0.4x EV/Sales on 2026 guidance.
Sources: Company filings, S&P Global estimates. Stock data as of market close February 17, 2026.